H. Lundbeck A/S/DKr HLUN B
08:00
10:00
12:00
13:55
15:55
1D1W1MYTD1Y5YMAX
About H. Lundbeck A/S
H. Lundbeck A/S is a Danish pharmaceutical company specializing in the research, development, and marketing of products for the treatment of brain diseases. The company focuses on areas such as depression, schizophrenia, Alzheimer's disease, and Parkinson's disease. Founded in 1915, Lundbeck is headquartered in Valby, Denmark, and has a significant global presence with facilities across Europe, North America, and Asia. Lundbeck's strategic positioning is underscored by its dedicated emphasis on central nervous system disorders, supported by a robust pipeline of research and development projects. The company places a strong emphasis on scientific and clinical excellence, aiming to deliver innovative therapies to improve patient outcomes.
Ticker
DKr HLUN B
Sector
Primary listing
CSE
Employees
5,039
Headquarters
Valby, Denmark
Website
H. Lundbeck A/S Metrics
BasicAdvanced
kr 37B
11.70
kr 3.22
0.34
kr 0.95
2.52%
Price and volume
Market cap
kr 37B
Beta
0.34
52-week high
kr 47.78
52-week low
kr 29.00
Average daily volume
878K
Dividend rate
kr 0.95
Financial strength
Current ratio
1.444
Quick ratio
0.902
Long term debt to equity
46.5
Total debt to equity
46.798
Dividend payout ratio (TTM)
29.54%
Interest coverage (TTM)
7.63%
Profitability
EBITDA (TTM)
7,655
Gross margin (TTM)
82.68%
Net profit margin (TTM)
12.96%
Operating margin (TTM)
23.88%
Effective tax rate (TTM)
28.86%
Revenue per employee (TTM)
kr 4,890,000
Management effectiveness
Return on assets (TTM)
6.85%
Return on equity (TTM)
12.79%
Valuation
Price to earnings (TTM)
11.705
Price to revenue (TTM)
1.517
Price to book
1.47
Price to tangible book (TTM)
-3.36
Price to free cash flow (TTM)
6.817
Free cash flow yield (TTM)
14.67%
Free cash flow per share (TTM)
5.525
Dividend yield (TTM)
2.52%
Forward dividend yield
2.52%
Growth
Revenue change (TTM)
11.93%
Earnings per share change (TTM)
1.50%
3-year revenue growth (CAGR)
10.52%
10-year revenue growth (CAGR)
5.37%
3-year earnings per share growth (CAGR)
18.58%
10-year earnings per share growth (CAGR)
-5.72%
3-year dividend per share growth (CAGR)
25.63%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for H. Lundbeck A/S stock?
H. Lundbeck A/S (HLUN B) has a market cap of DKr37B as of March 17, 2026.
What is the P/E ratio for H. Lundbeck A/S stock?
The price to earnings (P/E) ratio for H. Lundbeck A/S (HLUN B) stock is 11.7 as of March 17, 2026.
Does H. Lundbeck A/S stock pay dividends?
Yes, the H. Lundbeck A/S (HLUN B) stock pays dividends to shareholders. As of March 17, 2026, the dividend rate is DKr0.95 and the yield is 2.52%. H. Lundbeck A/S has a payout ratio of 29.54% on a trailing twelve-month basis.
When is the next H. Lundbeck A/S dividend payment date?
The next H. Lundbeck A/S (HLUN B) dividend payment is scheduled for March 23, 2026.
What is the beta indicator for H. Lundbeck A/S?
H. Lundbeck A/S (HLUN B) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.